Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the safety and feasibility of SBRT without ADT in
oligometastatic prostate cancer in patients for whom the standard treatment is ADT, and to
further explore how long only radiotherapy for oligometastases can prolong biochemical
progression-free survival (bPFS). In this study, men with oligometastatic prostate cancer
lesions will be randomized (1:1) to ADT versus SBRT. Within 6 weeks of the oligometastases
diagnosis, ADT or SBRT (30-50Gy with 3-5 fractions) will be administered.